Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

Key facts

Sponsor

C2N Diagnostics

Principal Investigator

Adam Boxer, MD, PhD

UCSF Memory and Aging Center

Intervention

Single dose C2N-8E12(drug)

Enrollment

32 enrolled

Eligibility

50-85 years · All sexes

Timeline

2015 – 2016

Study locations (12)

• University of Alabama, Birmingham, Alabama, United States
• Mayo Clinic, Scottsdale, Arizona, United States
• University of California, Los Angeles (UCLA), Los Angeles, California, United States
• UCSD Department of Neurosciences, San Diego, California, United States
• University of California, San Francisco, San Francisco, California, United States
• University of Florida College of Medicine, Gainesville, Florida, United States
• Mayo Clinic, Jacksonville, Florida, United States
• Indiana University Medical Center, Indianapolis, Indiana, United States
• Mayo Clinic, Rochester, Minnesota, United States
• Columbia University, New York, New York, United States
• Vanderbilt University Medical Center, Nashville, Tennessee, United States
• Texas Health Presbyterian Dallas, Dallas, Texas, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic progressive supranuclear palsy syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07509125
  Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
  Universitaire Ziekenhuizen KU Leuven
• RECRUITINGEARLY PHASE1NCT07348276
  First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
  Invicro
• RECRUITINGNANCT07291687
  tDCS as Treatment for Motor Function
  Baycrest
• ACTIVE NOT RECRUITINGNANCT06588673
  Art Therapy in Progressive Supranuclear Palsy
  Vanderbilt University Medical Center
• ENROLLING BY INVITATIONNANCT06597071
  Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely
  NeuraLight
• ACTIVE NOT RECRUITINGPHASE2NCT06355531
  A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
  Ferrer Internacional S.A.
• RECRUITINGNCT06949865
  AI-Enhanced Optimization of Acute Levodopa Challenge Test
  Beijing Tiantan Hospital
• RECRUITINGNANCT06174948
  The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders
  Queen Mary University of London

See all trials for Classic progressive supranuclear palsy syndrome →